Document Detail


Oral propafenone therapy for children with arrhythmias: efficacy and adverse effects in midterm follow-up.
MedLine Citation:
PMID:  1927853     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The use of oral propafenone was assessed in 57 children. Mean age was 4.8 +/- 5.2 years (range 1 day to 17 years). Twenty-three patients were less than 1 year of age (40%) and 10 were less than 1 month of age (18%). Arrhythmias included supraventricular tachycardia in 32 patients (57%), atrial flutter in six (10%), and ventricular tachycardia in 19 (33%). Cardiac diagnoses included: an otherwise normal heart in 30 (53%); unoperated congenital heart defect in 11 (19%); cardiomyopathy in nine (16%); and an operated congenital heart defect in seven (12%). Mean dose of propafenone was 13.1 mg/kg/day (range 8 to 15). Success (assessed by relief of symptoms and serial 24-hour ECGs) was achieved in 16 of 32 patients with supraventricular tachycardia (50%), three of six with atrial flutter (50%), and 8 of 19 with ventricular tachycardia (42%). Drug efficacy in patients with and without organic heart disease was 30% (8 of 27) and 63% (19 of 30), respectively (p less than 0.05). Mean duration of therapy in patients in whom the drug was effective was 22.9 +/- 13.2 months (range 6 to 60). Growth was unimpaired in all patients. A neonate with nonsustained monomorphic ventricular tachycardia had sustained ventricular tachycardia during the second day of propafenone therapy at a dose of 13 mg/kg/day. Sustained ventricular tachycardia disappeared when the drug was discontinued. Another patient had an asymptomatic and transient increase in the glutamic pyruvic transaminase level. No adverse hemodynamic effects were observed. In conclusion, propafenone is an effective antiarrhythmic drug in children with normal hearts; it is less effective in patients with heart disease.(ABSTRACT TRUNCATED AT 250 WORDS)
Authors:
P Guccione; F Drago; R M Di Donato; M P Cicini; L Pasquini; B Marino; C Marcelletti; P Ragonese
Related Documents :
1729853 - Efficacy and electrophysiologic effects of oral sotalol in patients with sustained vent...
1529903 - The prevalence of proarrhythmic events during moricizine therapy and their relationship...
12426513 - Pharmacokinetics of c1-inhibitor protein in patients with acute myocardial infarction.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American heart journal     Volume:  122     ISSN:  0002-8703     ISO Abbreviation:  Am. Heart J.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1991-10-31     Completed Date:  1991-10-31     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1022-7     Citation Subset:  AIM; IM    
Affiliation:
Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesu Hospital, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adolescent
Arrhythmias, Cardiac / diagnosis,  drug therapy*,  etiology
Atrial Flutter / drug therapy
Chi-Square Distribution
Child
Child, Preschool
Follow-Up Studies
Heart Defects, Congenital / complications
Humans
Infant
Infant, Newborn
Propafenone / administration & dosage,  adverse effects,  therapeutic use*
Tachycardia / drug therapy
Chemical
Reg. No./Substance:
54063-53-5/Propafenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe h...
Next Document:  Assessment of right ventricular diastolic and systolic function in patients with dilated cardiomyopa...